NO315682B1 - Kunstige ern¶ringsformuleringer inneholdende oligosakkarider - Google Patents

Kunstige ern¶ringsformuleringer inneholdende oligosakkarider Download PDF

Info

Publication number: NO315682B1
Authority: NO; Norway
Prior art keywords: approx; lacto; fucopentaose; oligosaccharides; fucosyllactose
Prior art date: 1997-03-31

Application number

NO19994621A

Other languages

English (en)

Norwegian (no)

Other versions

NO994621D0 (no

NO994621L (no

Inventor

Pedro A Prieto

Stephen J Kirchner

Renee M Erney

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-31

Filing date

1999-09-23

Publication date

2003-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25253688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO315682(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-23 Application filed by Abbott Lab filed Critical Abbott Lab

1999-09-23 Publication of NO994621D0 publication Critical patent/NO994621D0/no

1999-09-23 Publication of NO994621L publication Critical patent/NO994621L/no

2003-10-13 Publication of NO315682B1 publication Critical patent/NO315682B1/no

Links

229920001542 oligosaccharide Polymers 0.000 title claims abstract description 74
150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 74
239000000203 mixture Substances 0.000 title claims abstract description 37
235000016709 nutrition Nutrition 0.000 title claims abstract description 15
238000009472 formulation Methods 0.000 title abstract description 22
IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims abstract description 15
FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 claims abstract description 14
FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 claims abstract description 14
WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims abstract description 13
CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 claims abstract description 13
DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 claims abstract description 13
CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 claims abstract description 13
TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 claims abstract description 12
LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 claims abstract description 12
LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 claims abstract description 12
FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 claims abstract description 12
229940062780 lacto-n-neotetraose Drugs 0.000 claims abstract description 12
RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims abstract description 12
HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 9
229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 8
HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 8
SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 8
AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims abstract 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
239000008101 lactose Substances 0.000 claims description 14
235000013336 milk Nutrition 0.000 claims description 11
239000008267 milk Substances 0.000 claims description 11
210000004080 milk Anatomy 0.000 claims description 11
235000021073 macronutrients Nutrition 0.000 claims description 10
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
239000005862 Whey Substances 0.000 claims description 6
108010046377 Whey Proteins Proteins 0.000 claims description 6
102000007544 Whey Proteins Human genes 0.000 claims description 6
229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
239000011707 mineral Substances 0.000 claims description 5
235000010755 mineral Nutrition 0.000 claims description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
235000013305 food Nutrition 0.000 claims description 4
239000008103 glucose Substances 0.000 claims description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
108010073771 Soybean Proteins Proteins 0.000 claims description 3
239000011575 calcium Substances 0.000 claims description 3
229910052791 calcium Inorganic materials 0.000 claims description 3
239000003240 coconut oil Substances 0.000 claims description 3
235000019864 coconut oil Nutrition 0.000 claims description 3
239000010949 copper Substances 0.000 claims description 3
229910052802 copper Inorganic materials 0.000 claims description 3
229910052742 iron Inorganic materials 0.000 claims description 3
239000011777 magnesium Substances 0.000 claims description 3
229910052749 magnesium Inorganic materials 0.000 claims description 3
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
239000011574 phosphorus Substances 0.000 claims description 3
229910052698 phosphorus Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011669 selenium Substances 0.000 claims description 3
229910052711 selenium Inorganic materials 0.000 claims description 3
235000011649 selenium Nutrition 0.000 claims description 3
235000020183 skimmed milk Nutrition 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
229940001941 soy protein Drugs 0.000 claims description 3
235000012424 soybean oil Nutrition 0.000 claims description 3
235000019155 vitamin A Nutrition 0.000 claims description 3
239000011719 vitamin A Substances 0.000 claims description 3
235000019156 vitamin B Nutrition 0.000 claims description 3
239000011720 vitamin B Substances 0.000 claims description 3
235000019154 vitamin C Nutrition 0.000 claims description 3
239000011718 vitamin C Substances 0.000 claims description 3
235000019166 vitamin D Nutrition 0.000 claims description 3
239000011710 vitamin D Substances 0.000 claims description 3
235000019165 vitamin E Nutrition 0.000 claims description 3
239000011709 vitamin E Substances 0.000 claims description 3
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
229930003268 Vitamin C Natural products 0.000 claims description 2
229930003316 Vitamin D Natural products 0.000 claims description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
229930003427 Vitamin E Natural products 0.000 claims description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
239000003549 soybean oil Substances 0.000 claims description 2
150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
229940045997 vitamin a Drugs 0.000 claims description 2
239000011592 zinc chloride Substances 0.000 claims description 2
235000005074 zinc chloride Nutrition 0.000 claims description 2
AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 abstract description 9
AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 abstract description 7
USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 abstract description 7
235000020256 human milk Nutrition 0.000 description 29
210000004251 human milk Anatomy 0.000 description 25
235000013350 formula milk Nutrition 0.000 description 20
238000000034 method Methods 0.000 description 15
239000013589 supplement Substances 0.000 description 12
WJPIUUDKRHCAEL-YVEAQFMBSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O WJPIUUDKRHCAEL-YVEAQFMBSA-N 0.000 description 11
150000001720 carbohydrates Chemical class 0.000 description 9
235000010469 Glycine max Nutrition 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
239000012530 fluid Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
102000000340 Glucosyltransferases Human genes 0.000 description 4
108010055629 Glucosyltransferases Proteins 0.000 description 4
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
230000009469 supplementation Effects 0.000 description 4
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 3
230000010354 integration Effects 0.000 description 3
229950006780 n-acetylglucosamine Drugs 0.000 description 3
230000035764 nutrition Effects 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000006471 Fucosyltransferases Human genes 0.000 description 2
108010019236 Fucosyltransferases Proteins 0.000 description 2
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
239000000370 acceptor Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
AXQLFFDZXPOFPO-FSGZUBPKSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO AXQLFFDZXPOFPO-FSGZUBPKSA-N 0.000 description 2
NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000002597 lactoses Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
101100504522 Drosophila melanogaster glec gene Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010017964 Gastrointestinal infection Diseases 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000051366 Glycosyltransferases Human genes 0.000 description 1
108700023372 Glycosyltransferases Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000002481 ethanol extraction Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005417 food ingredient Substances 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
239000000383 hazardous chemical Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000021125 infant nutrition Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
235000013675 iodine Nutrition 0.000 description 1
230000006651 lactation Effects 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000003050 macronutrient Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000006180 nutrition needs Nutrition 0.000 description 1
238000004816 paper chromatography Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
235000016804 zinc Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Polymers & Plastics (AREA)
Nutrition Science (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Pediatric Medicine (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Dairy Products (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Jellies, Jams, And Syrups (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

NO19994621A 1997-03-31 1999-09-23 Kunstige ern¶ringsformuleringer inneholdende oligosakkarider NO315682B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/829,157 US6045854A (en)	1997-03-31	1997-03-31	Nutritional formulations containing oligosaccharides
PCT/US1998/006216 WO1998043494A1 (en)	1997-03-31	1998-03-30	Nutritional formulations containing oligosaccharides

Publications (3)

Publication Number	Publication Date
NO994621D0 NO994621D0 (no)	1999-09-23
NO994621L NO994621L (no)	1999-09-23
NO315682B1 true NO315682B1 (no)	2003-10-13

Family

ID=25253688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994621A NO315682B1 (no)	1997-03-31	1999-09-23	Kunstige ern¶ringsformuleringer inneholdende oligosakkarider

Country Status (12)

Country	Link
US (2)	US6045854A (de)
EP (1)	EP0975235B2 (de)
JP (2)	JP4863236B2 (de)
AT (1)	ATE326862T1 (de)
CA (1)	CA2285065C (de)
DE (1)	DE69834633T3 (de)
DK (1)	DK0975235T4 (de)
ES (1)	ES2265161T5 (de)
MX (1)	MX210206B (de)
NO (1)	NO315682B1 (de)
PT (1)	PT975235E (de)
WO (1)	WO1998043494A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19701382A1 (de) *	1997-01-16	1998-07-23	Nutricia Nv	Kohlenhydratmischung
US6329170B1 (en) *	1999-04-23	2001-12-11	Northwest Hospital	Nucleic acids and proteins of a rat ganglioside GM1-specific α1→2fucosyltransferase and uses thereof
DE19958985A1 (de) *	1999-12-07	2001-06-13	Nutricia Nv	Oligosaccharidmischung
EP1062873A1 (de) *	1999-12-13	2000-12-27	N.V. Nutricia	Verbessertes Säuglingsnährpräparat, Eiweisshydrolysat zur Verwendung in solchem Säuglingsnährpräparat, und Verfahren zur Herstellung solches Hydrolysates
DE10147100A1 (de) *	2001-09-25	2003-04-17	Numico Res B V	Antiinfektive Kohlenhydrate
DE10204000A1 (de) *	2002-02-01	2003-08-14	Nutricia Nv	Sialysierte Kohlenhydrate
US7977098B2 (en) *	2002-05-31	2011-07-12	Children's Hospital Medical Center	Antigenic binding patterns of norovirus to human histo-blood group antigens
EP1532279B1 (de) *	2002-05-31	2011-02-16	Children's Hospital Medical Center	Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
EP1531832B1 (de) *	2002-06-28	2009-04-15	Glykos Finland Oy	Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
CA2530170A1 (en) *	2003-06-24	2005-01-06	University Of Kansas Medical Center	Infant formula
CA2548140A1 (en) *	2003-12-05	2005-06-23	University Of Massachusetts	Oligosaccharide compositions and use thereof in the treatment of infection
ES1056525Y (es) *	2004-01-13	2004-07-16	Perez Alfredo Pineiro	Halador de tres rodillos para redes y aparejos de pesca.
PL1629850T5 (pl) *	2004-08-24	2013-09-30	Nutricia Nv	Kompozycja odżywcza zawierająca niestrawne transgalaktooligosacharydy i strawne galaktozosacharydy
MY146109A (en) *	2006-02-10	2012-06-29	Nestec Sa	Oligosaccharide mixture
US20110152263A1 (en) *	2006-11-16	2011-06-23	Xi Jiang	Composition and method for inhibiting norovirus infection
US8197872B2 (en) *	2007-05-17	2012-06-12	The Regents Of The University Of California	Human milk oligosaccharides to promote growth of beneficial gut bacteria
CN101855554B (zh)	2007-09-07	2014-05-14	儿童医院医学中心	分泌者、Lewis和唾液酸化抗原水平作为疾病预测指标的用途
EP2060257A1 (de) *	2007-11-08	2009-05-20	Nestec S.A.	Vorbeugung und Behandlung von Sekundärinfektionen nach Virusinfektion
AU2008324105B2 (en) *	2007-11-08	2014-01-30	Société des Produits Nestlé S.A.	Use of oligosaccharides containing N-acetyllactosamine for maturation of immune responses in neonates
EP2072052A1 (de)	2007-12-17	2009-06-24	Nestec S.A.	Verhinderung opportunistischer Infektionen bei Personen mit schwachem Immunsystem
PT2265135T (pt) *	2008-03-14	2018-02-21	Nestec Sa	Mistura simbiótica
US8927027B2 (en)	2008-12-02	2015-01-06	Prolacta Bioscience	Human milk permeate compositions and methods of making and using same
BRPI0923191A2 (pt) *	2008-12-19	2016-02-16	Momenta Pharmaceuticals Inc	metodos relacionados com glicanos modificados
CN102612525A (zh)	2009-06-09	2012-07-25	儿童医院医疗中心	抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
DK2451462T3 (en)	2009-07-06	2017-12-11	Children's Hospital Medical Center	Inhibition of inflammation with milk oligosaccharides
PL2453902T3 (pl) *	2009-07-15	2014-01-31	Nutricia Nv	Mieszanina niepodatnych na trawienie oligosacharydów do stymulowania układu immunologicznego
EP2767173A1 (de)	2010-04-27	2014-08-20	N.V. Nutricia	Verwendung von Muttermilch-Oligosaccharisden in Kindernahrung
WO2011136637A1 (en)	2010-04-27	2011-11-03	N.V. Nutricia	Use of human milk oligosaccharides in infant nutrition
WO2011150939A1 (en) *	2010-06-01	2011-12-08	Glycom A/S	Polymorphs of 2'-o-fucosyllactose and producing thereof
EP2454948A1 (de)	2010-11-23	2012-05-23	Nestec S.A.	Oligosaccharidmischung und Lebensmittel mit dieser Mischung, insbesondere Säuglingsnahrung
EP2465509A1 (de)	2010-11-23	2012-06-20	Nestec S.A.	Oligosaccharid Zusammensetzung zur Behandlung von akuten Atemwegsinfektionen
DK2658548T3 (en)	2010-12-31	2018-05-07	Abbott Lab	OLIGOSACCHARIDES OF MOTHER MILK FOR MODULATING INFLAMMATION
MX356994B (es)	2010-12-31	2018-06-22	Abbott Lab	Composiciones nutricionales que comprenden los oligosacaridos de leche humana y los nucleotidos y los usos de las mismas para tratar y/o prevenir la infeccion viral enterica.
WO2012092160A2 (en) *	2010-12-31	2012-07-05	Abbott Laboratories	Human milk oligosaccharides to promote growth of beneficial bacteria
CN103369974A (zh)	2010-12-31	2013-10-23	雅培制药有限公司	包含人乳低聚糖和长链多不饱和脂肪酸的营养型制剂以及其用途
EP2658402A1 (de) *	2010-12-31	2013-11-06	Abbott Laboratories	Symbiotische zusammensetzung probiotischer und menschlicher milcholigosaccharide zur anregung des wachstums von günstiger darmflora
MX2013007692A (es)	2010-12-31	2013-08-15	Abbott Lab	Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
EP3473257A1 (de) *	2010-12-31	2019-04-24	Abbott Laboratories	Verfahren zur verwendung menschlicher milcholigosaccharide zur verbesserung des gesundheitszustandes der atemwege
EP2658549B1 (de)	2010-12-31	2020-06-03	Abbott Laboratories	Verfahren zur reduzierung des auftretens von oxidativem stress unter verwendung von menschlichen milcholigosacchariden, vitamin c und entzündungshemmern
EP2522232A1 (de) *	2011-05-13	2012-11-14	Nestec S.A.	Nahrungsmittel mit menschlichen Milcholigosacchariden und Herstellungsverfahren dafür
JP6129821B2 (ja)	2011-05-13	2017-05-17	グリコシンリミテッドライアビリティーカンパニー	プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
EP2526784A1 (de)	2011-05-24	2012-11-28	Nestec S.A.	Milcholigosaccharid-Galactooligosaccharid-Zusammensetzung für Kindernahrung mit niedrigem Monosaccharidgehalt, enthaltend die in der Milch vorhandene lösliche Oligosaccharidfraktion, sowie ein Verfahren zur Herstellung der Zusammensetzung
EP2734210B1 (de) *	2011-07-22	2017-11-22	Abbott Laboratories	Galactooligosaccharide zur prävention von verletzungen und/oder förderung der heilung des magen-darm-traktes
BR112014004772A2 (pt) *	2011-08-29	2017-03-21	Abbott Lab	oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
CN104812768B (zh) *	2012-11-13	2019-06-21	格礼卡姆股份公司	晶体3-o-岩藻糖基乳糖
EP2931737A4 (de) *	2012-12-14	2016-11-16	Glycom As	Mischung aus fucosylatlactosen
EP2745705A1 (de) *	2012-12-18	2014-06-25	Abbott Laboratories	Ernährungsbedingte Verwendung von Muttermilch Oligosacchariden
US10626460B2 (en)	2013-02-21	2020-04-21	Children's Hospital Medical Center	Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US20160113952A1 (en)	2013-05-22	2016-04-28	Glycom As	Synthetic Mixture of Oligosaccharides for Treating a Microbiota of a Mammal
US9321803B2 (en)	2013-07-12	2016-04-26	Children's Hospital Medical Center	Compositions and methods for inhibiting norovirus infection
CN114468302A (zh)	2013-11-15	2022-05-13	雀巢产品有限公司	用于预防或治疗有风险婴儿或幼儿的urt感染的组合物
MX2016013064A (es)	2014-04-08	2017-01-26	Abbott Lab	Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
CN106714583A (zh) *	2014-09-25	2017-05-24	雀巢产品技术援助有限公司	具有自适应水平的人乳寡糖(hmo)的婴儿配方食品体系
US10314852B2 (en)	2014-10-24	2019-06-11	Glycom A/S	Mixtures of HMOs
AU2015340652B9 (en) *	2014-10-31	2020-04-16	Société des Produits Nestlé S.A.	Composition comprising Fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
FI3264923T3 (fi)	2015-03-05	2023-04-21	Nestle Sa	Koostumuksia käytettäväksi ruoansulatuskanavan infektioiden ehkäisemisessä tai hoitamisessa imeväisillä tai nuorilla lapsilla
RU2720201C2 (ru) *	2015-03-05	2020-04-27	Сосьете Де Продюи Нестле С.А.	Композиции для применения в профилактике или лечении отита или бронхита у младенцев или детей младшего возраста
WO2016176484A1 (en)	2015-04-28	2016-11-03	Children's Hospital Medical Center	Use of oligosaccharide compositions to enhance weight gain
US20180220690A1 (en) *	2015-08-04	2018-08-09	Nestec S.A.	Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants
ES2759556T3 (es)	2015-12-15	2020-05-11	Nestle Sa	Mezcla de oligosacáricos de la leche humana
CN108495635A (zh) *	2016-01-26	2018-09-04	雀巢产品技术援助有限公司	人乳低聚糖对抗日后的脂肪量过度积聚和相关的健康障碍
AU2017211272B2 (en) *	2016-01-26	2022-04-21	Société des Produits Nestlé S.A.	Human milk oligosaccharides for health benefits by prevention of premature adiposity rebound
EP3515195A4 (de) *	2016-09-19	2020-05-27	Prolacta Bioscience, Inc.	Gereinigte oligosaccharide zusammensetzungen der menschlichen milch
US20180103675A1 (en)	2016-10-14	2018-04-19	Mead Johnson Nutrition Company	Personalized pediatric nutrition products comprising human milk oligosaccharides
US10980269B2 (en) *	2016-12-12	2021-04-20	Mead Johnson Nutrition Company	Protein hydrolysates and methods of making same
JP2020515531A (ja)	2017-03-28	2020-05-28	チルドレンズホスピタルメディカルセンター	ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
US20200108084A1 (en)	2017-05-24	2020-04-09	Societe Des Produits Nestle S.A.	Composition comprising oligofructose (of) for use in the improvement of short term memory and other cognitive benefits
CN110799045A (zh)	2017-05-24	2020-02-14	雀巢产品有限公司	用于改善短期记忆和其他认知益处的包含人乳低聚糖(hmo)的组合物
CN111093395A (zh)	2017-07-07	2020-05-01	雀巢产品有限公司	人乳强化剂
CN110868872A (zh)	2017-07-07	2020-03-06	雀巢产品有限公司	人乳强化剂
WO2019008102A1 (en)	2017-07-07	2019-01-10	Nestec S.A.	FORTIFYING HUMAN MILK
US11197917B2 (en)	2017-12-01	2021-12-14	ByHeart, Inc.	Formulations for nutritional support in subjects in need thereof
EP3546060A1 (de) *	2018-03-27	2019-10-02	DuPont Nutrition Biosciences ApS	Verfahren zur sprühtrocknung von fucosyllactoselösungen und verwandte produktzusammensetzungen
WO2019160922A1 (en) *	2018-02-19	2019-08-22	Dupont Nutrition Biosciences Aps	Process for spray drying fucosyllactose solutions and related product compositions
AU2019296552B2 (en)	2018-06-25	2024-10-10	Societe Des Produits Nestle S.A.	Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a serotonergic function in the central nervous system
WO2020001863A1 (en)	2018-06-25	2020-01-02	Societe Des Produits Nestle S.A.	Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a gabaergic function in the central nervous system
CN113226064A (zh) *	2018-12-20	2021-08-06	雀巢产品有限公司	人乳强化剂组合物
AU2020287909A1 (en) *	2019-06-04	2021-08-19	N.V. Nutricia	Nutritional composition comprising 2'fucosyllactose and 3'galactosyllactose
WO2021015977A1 (en) *	2019-07-23	2021-01-28	Dupont Nutrition Biosciences Aps	Oral healthcare treatment and related compositions
ES1240969Y (es) *	2019-09-18	2020-07-30	Jennewein Biotechnologie Gmbh	Composiciones de cereales que contienen oligosacaridos de la leche humana
GB2590375B (en) *	2019-12-11	2024-05-08	Mjn Us Holdings Llc	Staged nutritional compositions containing human milk oligosaccharides and uses thereof
TW202233201A (zh)	2020-12-16	2022-09-01	荷蘭商弗里斯蘭康必奶荷蘭有限公司	包含ＬＮＦＰＩＩＩ和ＬＳＴａ的合成組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5951264B2 (ja) *	1981-11-30	1984-12-13	雪印乳業株式会社	オリゴ糖含有粉末の製造方法
DD273543A3 (de) *	1987-09-14	1989-11-22	Univ Rostock	Verfahren zur herstellung von saeuglings- und diaetnahrungen mit hypoantigener, bifidogener wirkung
SE462134B (sv) *	1987-10-22	1990-05-14	Biocarb Ab	Livsmedel innehaallande lacto-n-tetraos och foerfarande foer dess framstaellning
DE3876986D1 (de) *	1988-07-07	1993-02-04	Milupa Ag	Verfahren zur enzymatischen herstellung von bifidogener saeuglings- und diaetnahrung.
US5095106A (en) *	1989-07-25	1992-03-10	Colgate-Palmolive	Olgiosaccharide inhibition of Streptococcus pyogenes adhesion
EP0481038B1 (de) *	1990-04-16	2002-10-02	The Trustees Of The University Of Pennsylvania	Saccharidzusammensetzungen, Verfahren und Apparate zu deren Synthese
US5021245A (en) *	1990-05-22	1991-06-04	Abbott Laboratories	Infant formula containing a soy polysaccharide fiber source
CN1129953A (zh) *	1993-07-15	1996-08-28	尼奥斯药品公司	糖组分的合成方法
US5750176A (en) *	1994-03-09	1998-05-12	Abbott Laboratories	Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
JPH0838064A (ja) *	1994-07-26	1996-02-13	Meiji Seika Kaisha Ltd	有害細菌の感染を予防する飼料
US5545553A (en) *	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5827526A (en) *	1995-07-11	1998-10-27	Abbott Laboratories	Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans

1997
- 1997-03-31 US US08/829,157 patent/US6045854A/en not_active Expired - Lifetime
1998
- 1998-03-30 WO PCT/US1998/006216 patent/WO1998043494A1/en active IP Right Grant
- 1998-03-30 CA CA2285065A patent/CA2285065C/en not_active Expired - Lifetime
- 1998-03-30 PT PT98912118T patent/PT975235E/pt unknown
- 1998-03-30 AT AT98912118T patent/ATE326862T1/de active
- 1998-03-30 ES ES98912118.1T patent/ES2265161T5/es not_active Expired - Lifetime
- 1998-03-30 EP EP98912118.1A patent/EP0975235B2/de not_active Expired - Lifetime
- 1998-03-30 DE DE69834633.5T patent/DE69834633T3/de not_active Expired - Lifetime
- 1998-03-30 JP JP54189298A patent/JP4863236B2/ja not_active Expired - Fee Related
- 1998-03-30 DK DK98912118.1T patent/DK0975235T4/da active
- 1998-12-18 US US09/216,056 patent/US6146670A/en not_active Expired - Lifetime
1999
- 1999-09-23 NO NO19994621A patent/NO315682B1/no not_active IP Right Cessation
- 1999-09-29 MX MX9908953A patent/MX210206B/es unknown
2011
- 2011-09-07 JP JP2011195159A patent/JP2012036192A/ja active Pending

Also Published As

Publication number	Publication date
DE69834633D1 (de)	2006-06-29
EP0975235A1 (de)	2000-02-02
ES2265161T5 (es)	2014-03-24
US6146670A (en)	2000-11-14
ES2265161T3 (es)	2007-02-01
JP4863236B2 (ja)	2012-01-25
MX9908953A (es)	2000-01-31
PT975235E (pt)	2006-10-31
CA2285065C (en)	2011-07-19
NO994621D0 (no)	1999-09-23
ATE326862T1 (de)	2006-06-15
EP0975235B2 (de)	2014-01-15
US6045854A (en)	2000-04-04
JP2001517949A (ja)	2001-10-09
NO994621L (no)	1999-09-23
DE69834633T3 (de)	2014-05-08
CA2285065A1 (en)	1998-10-08
MX210206B (es)	2002-09-06
DK0975235T3 (da)	2006-10-02
JP2012036192A (ja)	2012-02-23
WO1998043494A1 (en)	1998-10-08
DK0975235T4 (da)	2014-03-31
DE69834633T2 (de)	2007-05-03
EP0975235B1 (de)	2006-05-24

Publication	Publication Date	Title
NO315682B1 (no)	2003-10-13	Kunstige ern¶ringsformuleringer inneholdende oligosakkarider
MXPA99008953A (en)	2000-01-01	Nutritional formulations containing oligosaccharides
US5292723A (en)	1994-03-08	Liquid nutritional compositions comprising slowly absorbed glucides
EP2046149B1 (de)	2010-11-03	Angereicherte säuglingsanfangsnahrung
CN101925307B (zh)	2013-02-13	高能量液体肠营养组合物
NO315254B1 (no)	2003-08-11	Ern¶ringsformuleringer inneholdende Lacto-N-neotetraose
US5455235A (en)	1995-10-03	Food composition for inhibiting the formation of an intestinal putrefactive product
WO2012027285A1 (en)	2012-03-01	Nutritional products having improved organoleptic properties
MXPA02007627A (es)	2003-01-28	Sistema de carbohidrato y metodo para proporcionar nutricion a un diabetico.
TW201717782A (zh)	2017-06-01	營養組成物及促進認知發展之方法
AU2014306366B2 (en)	2020-03-12	Sugar cane derived extracts and methods of treatment
WO2012027287A1 (en)	2012-03-01	Nutritional products including pea protein hydrolysates
Jansen et al.	2017	Development of enteral homemade diets for elderly persons receiving home care and analysis of macro and micronutrient composition
CN105050427A (zh)	2015-11-11	可食用组合物以及包含其的食品、该食品的制备方法
WO2015071478A1 (en)	2015-05-21	FRUIT JUICE COMPRISING β-GLUCAN AND A HYDROCOLLOID
Behrens	1993	The impact of oral rehydration and other therapies on the management of acute diarrhoea
CN107467569A (zh)	2017-12-15	一种增强人体免疫力的香菇复方制剂及其制备方法
Handana et al.	2019	Vitamin E and Vitamin C Intake Among Lactating Mothers In Jakarta
CN116941716A (zh)	2023-10-27	一种烧仙草颗粒水果饮料及其制备方法
JP4049278B2 (ja)	2008-02-20	腸内代謝改善剤
WO2024223906A1 (en)	2024-10-31	Composition for use in a subject
JPH05339159A (ja)	1993-12-21	抗脂血及び抗肥満剤
WO2014160476A1 (en)	2014-10-02	Prebiotic composition and method of its use
Vieira et al.	1996	Composition and Nutritional Value of Foods
Musa	2014	Nahla Tariq Khalid

Legal Events

Date	Code	Title	Description
2014-11-03	MM1K	Lapsed by not paying the annual fees